Loading...
NPI 1083382592 · Olive Branch, MS · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Precision Life Sciences LLC is a clinical medical laboratory provider located in Olive Branch, Mississippi. This profile covers 75 Medicare and 58 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Precision Life Sciences LLC |
| Address | 4850 Goodman Rd Ste 101 |
| City | Olive Branch |
| State | MS |
| ZIP | 38654 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 31, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.4M |
| Medicaid | $855.2K |
PRECISION LIFE SCIENCES LLC’s billing mix is dominated by molecular infectious-disease testing: its top Medicare revenue drivers are 87798, 87150, and 87481, and its top Medicaid drivers are U0003, U0005, and U0004. The Medicare top codes are all amplified nucleic acid probe tests and the Medicaid leaders include SARS‑CoV‑2 high‑throughput detection codes, indicating the operation is organized around high-volume molecular diagnostics and COVID testing workflows.
Revenue is highly concentrated within a small set of tests for both payers: the top three Medicare codes account for 68.5% of the provider’s total Medicare revenue, and the top three Medicaid codes account for 80.0% of the provider’s total Medicaid revenue. This concentration means a handful of molecular/COVID assays drive the bulk of the $2.4M in Medicare revenue and $855.2K in Medicaid revenue reported.
The payer mix is Medicare‑heavy in scale: the provider reports $2.4M in Medicare revenue versus $855.2K in Medicaid revenue, making Medicare the larger single revenue source on file. Both payers are active, but Medicare represents the primary revenue pool for this entity.
On national Medicare benchmarks the provider posts relatively high ranks for its leading infectious‑disease tests: 87798 ranks #76 of 1319 (94th percentile), 87150 ranks #25 of 190 (87th percentile), and 87481 ranks #62 of 1117 (95th percentile), though each code is labeled as "typical, unremarkable volume for this code." In other words, these are above‑median national positions for molecular testing but are described in the dataset with the provided label of typical/unremarkable volume.
Within Mississippi Medicaid the provider shows strong placement on COVID and related testing: U0003 ranks #4 of 56 (95th percentile), U0005 ranks #3 of 40 (95th percentile), and U0004 ranks #3 of 30 (93th percentile), each described as "typical, unremarkable volume for this code," while 87500 ranks #1 of 10 (100th percentile) and is labeled "notably above typical state volume for this code." This pattern indicates the lab is a significant statewide source for high‑throughput COVID assays and stands out for specific resistance testing.
Operational throughput appears substantial based on claim counts: Medicare shows 24.6K claims for 87798 and 14.5K claims for 87150, and Medicaid shows 12.5K claims for U0005 and 9.8K claims for U0003. Those multi‑thousand claim lines, combined with many lower‑paid per‑claim COVID codes, imply a high‑volume, low‑margin testing model focused on automated, high‑throughput assays and specimen logistics.
The provider also bills a modest but visible portfolio of non‑infectious assays and specimen services: Medicare lists 81226 at $48.5K (2.1% of Medicare revenue) and 81418 at $12.4K (0.5% of Medicare revenue), plus P9603 travel allowance with 10K claims and $10K revenue. These entries suggest some diversification into pharmacogenomic testing and home/nursing‑home specimen collection, but those lines remain small relative to the core molecular infectious testing revenue.
PRECISION LIFE SCIENCES LLC’s NPI was enumerated on 2021-08-31 (~5 years ago), a relatively recent enrollment given the reported volumes. The combination of a recent start date with multi‑thousand claim lines for key molecular assays suggests rapid operational scale‑up in a specialized diagnostic niche.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
75 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 24,560 | $30 | $835K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 14,460 | $30 | $491.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 7,180 | $30 | $244.2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 2,140 | $70 | $147.8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,930 | $70 | $142.7K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,860 | $30 | $63.2K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 1,850 | $30 | $62.9K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 110 | $440 | $48.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,930 | $30 | $48.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 1,270 | $30 | $43.2K |
Showing 1–10 of 75
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
75 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 1 | 10 | 14,460 | $30 | $497.3K |
| 87798 | 2 | 50 | 1,050 | $30 | $144.9K |
| 87481 | 2 | 40 | 540 | $30 | $61.5K |
| U0003 | 1 | 10 | 270 | $70 | $51.4K |
| P9603 | 2 | 10 | 5,240 | $1 | $29.8K |
| 87801 | 1 | 30 | 290 | $70 | $29.7K |
| 81226 | 1 | 10 | 60 | $440 | $27.4K |
| 87631 | 5 | 10 | 60 | $140 | $22.8K |
| U0005 | 1 | 10 | 250 | $20 | $15.9K |
| 87500 | 2 | 30 | 130 | $30 | $14.5K |
Showing 1–10 of 75
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
58 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 9,810 | $40 | $353.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 12,520 | $10 | $162.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3,240 | $50 | $158.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1,980 | $30 | $63.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 1,660 | $10 | $18.3K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 240 | $60 | $15.1K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 830 | $10 | $10.8K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 390 | $20 | $8.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,690 | $1 | $5.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 1,250 | $1 | $5K |
Showing 1–10 of 58
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
58 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4 | 60 | 190 | $40 | $111.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 101 | 230 | 1,870 | $10 | $70.1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3 | 30 | 310 | $60 | $62.8K |
| 83880 | The lab analyst measures the amount of natriuretic peptide, a hormone made by heart muscle cells, in the patient specimen. Blood levels of the hormone increase in patients with congestive heart… | 92 | 100 | 1,620 | $20 | $52.2K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 64 | 130 | 670 | $20 | $44.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 11 | 20 | 190 | $60 | $44.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 102 | 250 | 270 | $30 | $41.8K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 170 | 440 | 1,410 | $1 | $40.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 75 | 140 | 940 | $10 | $34.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4 | 40 | 160 | $30 | $33.2K |
Showing 1–10 of 58
Other providers in the same ZIP code as Precision Life Sciences LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Methodist Healthcare - Olive Branch Hospital | MS | General Acute Care Hospital | $0 | $18.1M |
| Region Iv The Hub | MS | Community/Behavioral Health Agency | $0 | $4.6M |
| Kls Medical Services | MS | In Home Supportive Care Agency | $0 | $4.4M |
| Sidhu Pediatrics, LLC | MS | Pediatrics Physician | $0 | $3.4M |
| Charles Ryan | MS | Obstetrics & Gynecology Physician | $4.5K | $1.5M |
| Calvin Brown | MS | Ophthalmology Physician | $1.2M | $0 |
| City Of Olive Branch | MS | Land Ambulance | $409.9K | $659.7K |
| Robert Pickering | MS | Orthopaedic Surgery Physician | $345.7K | $0 |
| Randall Huling | MS | Family Medicine Physician | $321.7K | $0 |
| Shailesh Patel | MS | Internal Medicine Physician | $202.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.